Literature DB >> 11495044

Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype.

Y Ito1, H Kawakatsu, T Takeda, M Sakon, H Nagano, T Sakai, E Miyoshi, K Noda, M Tsujimoto, K Wakasa, M Monden, N Matsuura.   

Abstract

BACKGROUND/AIMS: The aim of this study was to investigate whether c-Src is involved in carcinogenesis and progression of human hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma.
METHODS: We designed an immunohistochemical study using Clone 28, an antibody that specifically recognizes the activated form of c-Src.
RESULTS: Hepatocytes in normal liver, chronic hepatitis with or without cirrhosis, atypical adenomatous hyperplasia, as well as bile ductular cells, and infiltrating mononuclear cells were all negative for immunohistochemical staining for the activated c-Src. Among 87 cases of HCC tested, 40 (46%) were positively stained for the activated c-Src, and this positive staining was inversely correlated with the Ki-67 labeling index (LI) (P = 0.0031), intrahepatic metastasis (P = 0.0099), TNM stage (P = 0.0062), alpha-fetoprotein (P = 0.0103) and epidermal growth factor-receptor expression (P = 0.0153). Positive staining for the activated c-Src was more frequently observed in well- or moderately-differentiated carcinoma (P = 0.0256). In multivariate analysis, the activated c-Src expression was independently related to the Ki-67 LI (P = 0.0197). In contrast to positive staining in HCC, cholangiocarcinoma were classified as negative in all 19 cases examined.
CONCLUSIONS: These results strongly suggest the involvement of activated c-Src in early stages of HCC, and suggest that cholangiocarcinoma might employ different signaling mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495044     DOI: 10.1016/s0168-8278(01)00077-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  15 in total

Review 1.  Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Authors:  Michael Hopfner; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

2.  Elevated Src expression associated with hepatocellular carcinoma metastasis in northern Chinese patients.

Authors:  Ran Zhao; Yiqi Wu; Tianzhen Wang; Yuhua Zhang; Dan Kong; Lei Zhang; Xiaobo Li; Guangyu Wang; Yinji Jin; Xiaoming Jin; Fengmin Zhang
Journal:  Oncol Lett       Date:  2015-09-16       Impact factor: 2.967

3.  Initiation factor eIF2-independent mode of c-Src mRNA translation occurs via an internal ribosome entry site.

Authors:  Heba Allam; Naushad Ali
Journal:  J Biol Chem       Date:  2009-12-22       Impact factor: 5.157

Review 4.  SUMOylation and phosphorylation cross-talk in hepatocellular carcinoma.

Authors:  Maria Lauda Tomasi; Komal Ramani
Journal:  Transl Gastroenterol Hepatol       Date:  2018-04-23

5.  Evaluation of FAK and Src expression in human benign and malignant thyroid lesions.

Authors:  Christina Michailidi; Costas Giaginis; Vassilios Stolakis; Paraskevi Alexandrou; Jerzy Klijanienko; Ioanna Delladetsima; Nicolaos Chatzizacharias; Gerasimos Tsourouflis; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2010-04-20       Impact factor: 3.201

6.  Plasmin-Binding Tripeptide-Decorated Liposomes Loading Pyrazolo[3,4-d]pyrimidines for Targeting Hepatocellular Carcinoma.

Authors:  Pierpaolo Calandro; Giulia Iovenitti; Claudio Zamperini; Francesca Candita; Elena Dreassi; Mario Chiariello; Adriano Angelucci; Silvia Schenone; Maurizio Botta; Arianna Mancini
Journal:  ACS Med Chem Lett       Date:  2018-05-07       Impact factor: 4.345

7.  Amplification of MPZL1/PZR gene in hepatocellular carcinoma.

Authors:  Yao-Tsung Yeh; Hong-Ying Dai; Ching-Yen Chien
Journal:  Hepatobiliary Surg Nutr       Date:  2014-04       Impact factor: 7.293

8.  Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro.

Authors:  Grace M Lau; Gillian M Lau; Guo-Liang Yu; Irwin H Gelman; Alan Gutowski; David Hangauer; Jane W S Fang
Journal:  Dig Dis Sci       Date:  2008-11-01       Impact factor: 3.199

9.  Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer.

Authors:  Carmen Berasain; María Ujue Latasa; Raquel Urtasun; Saioa Goñi; María Elizalde; Oihane Garcia-Irigoyen; María Azcona; Jesús Prieto; Matías A Avila
Journal:  Cancers (Basel)       Date:  2011-05-18       Impact factor: 6.639

10.  Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish.

Authors:  Jeng-Wei Lu; Wan-Yu Yang; Su-Mei Tsai; Yueh-Min Lin; Pen-Heng Chang; Jim-Ray Chen; Horng-Dar Wang; Jen-Leih Wu; Shiow-Lian Catherine Jin; Chiou-Hwa Yuh
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.